1
|
Azzahra F, Amalia R, Karsono AH, Tjandrawinata RR, Ismaya WT, Rachmawati H. The mannose-binding protein from Agaricus bisporus inhibits the growth of MDA-MB-231 spheroids. Chem Biol Drug Des 2024; 103:e14365. [PMID: 37749066 DOI: 10.1111/cbdd.14365] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2023] [Revised: 09/02/2023] [Accepted: 09/19/2023] [Indexed: 09/27/2023]
Abstract
A mannose-binding protein from the mushroom Agaricus bisporus (Abmb) inhibits the growth of MDA-MB-231 cells, which is of an aggressive breast cancer subtype. This ability was observed in a monolayer cell (2D) culture setup, which often is unable to capture changes in cell morphology, polarity and division. That shortcoming may overestimate Abmb potency for its development as a pharmaceutical agent and its use in a therapy. Hence, Abmb's inhibition to the cell growth was performed in the 3D cell (spheroid) culture, which is more representative to the situation in vivo. The result showed that, although the presence of Abmb at ~14.7 μM already disrupted the MDA-MB-231 cell morphology in the 2D culture, its presence at ~16.5 μM only ceased the growth of the MDA-MB-231 spheroid. Further, Abmb is unique because structurally it belongs to the R-type lectin (RTL) family; most of mannose-binding protein is of the C-type lectin (CTL). As the natural ligand of Abmb is unknown thus the mechanism of action is unclear, Abmb effect on the cancer cells was assessed via observation of the altered expression of genes involved in the Wnt/β-catenin signalling, which is one of the canonical pathways in the proliferation of cancer cells. The results suggested that Abmb did not alter the pathway upon exerting its anti-proliferative activity to the MDA-MB-231 cells.
Collapse
Affiliation(s)
- Fauzia Azzahra
- Research Group of Pharmaceutics, School of Pharmacy, Bandung Institute of Technology, Bandung, Indonesia
| | - Riezki Amalia
- Department of Pharmacology and Clinical Pharmacy, Padjadjaran University, Jatinangor, Indonesia
| | - Agung Heru Karsono
- Dexa Laboratories of Biomolecular Sciences, Dexa Medica, Cikarang, Indonesia
| | - Raymond Rubianto Tjandrawinata
- Dexa Laboratories of Biomolecular Sciences, Dexa Medica, Cikarang, Indonesia
- Faculty of Biotechnology, Atma Jaya Catholic University of Indonesia, Tangerang, Indonesia
| | - Wangsa Tirta Ismaya
- Dexa Laboratories of Biomolecular Sciences, Dexa Medica, Cikarang, Indonesia
| | - Heni Rachmawati
- Research Group of Pharmaceutics, School of Pharmacy, Bandung Institute of Technology, Bandung, Indonesia
- Research Center for Nanosciences and Nanotechnology, Bandung Institute of Technology, Bandung, Indonesia
| |
Collapse
|
2
|
Tirta Ismaya W, Tjandrawinata RR, Rachmawati H. Lectins from the Edible Mushroom Agaricus bisporus and Their Therapeutic Potentials. Molecules 2020; 25:E2368. [PMID: 32443732 PMCID: PMC7287795 DOI: 10.3390/molecules25102368] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2020] [Revised: 05/09/2020] [Accepted: 05/09/2020] [Indexed: 01/02/2023] Open
Abstract
The mushroom Agaricus bisporus secretes biologically active compounds and proteins with benefits for human health. Most reported proteins from A. bisporus are tyrosinases and lectins. Lectins are of therapeutic or pharmaceutical interest. To date, only limited information is available on A. bisporus lectins and lectin-like proteins. No therapeutic products derived from A. bisporus lectin (ABL) are available on the market despite its extensive exploration. Recently, A. bisporus mannose-binding protein (Abmb) was discovered. Its discovery enriches the information and increases the interest in proteins with therapeutic potential from this mushroom. Furthermore, the A. bisporus genome reveals the possible occurrence of other lectins in this mushroom that may also have therapeutic potential. Most of these putative lectins belong to the same lectin groups as ABL and Abmb. Their relationship is discussed. Particular attention is addressed to ABL and Abmb, which have been explored for their potential in medicinal or pharmaceutical applications. ABL and Abmb have anti-proliferative activities toward cancer cells and a stimulatory effect on the immune system. Possible scenarios for their use in therapy and modification are also presented.
Collapse
Affiliation(s)
- Wangsa Tirta Ismaya
- Dexa Laboratories of Biomolecular Sciences, Dexa Medica, Industri Selatan V PP-7, Jababeka 2, Cikarang 17550, Indonesia; (W.T.I.); (R.R.T.)
| | - Raymond Rubianto Tjandrawinata
- Dexa Laboratories of Biomolecular Sciences, Dexa Medica, Industri Selatan V PP-7, Jababeka 2, Cikarang 17550, Indonesia; (W.T.I.); (R.R.T.)
| | - Heni Rachmawati
- School of Pharmacy, Bandung Institute of Technology, Ganesha 10, Bandung 40132, Indonesia
- Research Center for Nanosciences and Nanotechnology, Bandung Institute of Technology, Ganesha 10, Bandung 40132, Indonesia
| |
Collapse
|
3
|
Ismaya WT, Tjandrawinata RR, Dijkstra BW, Beintema JJ, Nabila N, Rachmawati H. Relationship of Agaricus bisporus mannose-binding protein to lectins with β-trefoil fold. Biochem Biophys Res Commun 2020; 527:1027-1032. [PMID: 32439171 DOI: 10.1016/j.bbrc.2020.05.030] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2020] [Accepted: 05/06/2020] [Indexed: 01/11/2023]
Abstract
Agaricus bisporus mannose-binding protein (Abmb) was discovered as part of the mushroom tyrosinase (PPO3) complex, but its function in the mushroom has remained obscure. The protein has a β-trefoil structure that is common for Ricin-B-like lectins. Indeed, its closest structural homologs are the hemagglutinin components of botulinum toxin (HA-33) and the Ricin-B-like lectin from Clitocybe nebularis (CNL), both of which bind galactose, and actinohivin, a recently discovered mannose-binding lectin from actinomycetes. Here we show that Abmb is evolutionarily related to them, which are lectins with a β-trefoil fold. We also show for the first time that Abmb can exhibit typical lectin agglutination activity but only when in the complex with mushroom tyrosinase. This is unexpected and unique because the two proteins are not evolutionarily related and have different activities. Lectin and tyrosinase major role in defense mechanism as well as Abmb and PPO3 gene regulation during the early stages of the development of mushroom fruiting bodies suggested that Abmb has likely a function in defense against bacterial infection and/or insect-induced damage.
Collapse
Affiliation(s)
- Wangsa T Ismaya
- Dexa Laboratories of Biomolecular Sciences, Industri Selatan V Blok PP-7, JABABEKA II Industrial Estate, 17550, Cikarang, Indonesia.
| | - Raymond R Tjandrawinata
- Dexa Laboratories of Biomolecular Sciences, Industri Selatan V Blok PP-7, JABABEKA II Industrial Estate, 17550, Cikarang, Indonesia
| | - Bauke W Dijkstra
- Laboratory of Biophysical Chemistry, University of Groningen, Nijenborgh 7, 9747, AG Groningen, the Netherlands
| | - Jaap J Beintema
- Laboratory of Biochemistry, University of Groningen, Nijenborgh 4, 9747, AG Groningen, the Netherlands
| | - Najwa Nabila
- Research Group of Pharmaceutics, School of Pharmacy and Research Center for Nanosciences and Nanotechnology, Bandung Institute of Technology, Ganesa 10, 40132, Bandung, Indonesia
| | - Heni Rachmawati
- Research Group of Pharmaceutics, School of Pharmacy and Research Center for Nanosciences and Nanotechnology, Bandung Institute of Technology, Ganesa 10, 40132, Bandung, Indonesia.
| |
Collapse
|
4
|
Nabila N, Meidianto VF, Tjandrawinata RR, Rachmawati H, Ismaya WT. Agaricus bisporus mannose binding protein is not an agglutinating protein. Biochem Biophys Res Commun 2019; 519:773-6. [PMID: 31547987 DOI: 10.1016/j.bbrc.2019.09.071] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2019] [Accepted: 09/17/2019] [Indexed: 11/21/2022]
Abstract
Agaricus bisporus mannose binding protein (Abmb) demonstrates permeability to epithelial monolayer barrier of the intestine, resistance to gastrointestinal tract conditions and to proteolysis therefore it holds potential as a drug carrier for oral route administration. Abmb also display antiproliferative activity to breast cancer cells and stimulation of immune system thus could potentially be also developed for therapeutic purpose. It is not immunogenic or toxic thereby safe for use. In this paper we further provide evidence that Abmb also lacks of agglutinating activity despite sharing high structural homology to lectins. Abmb is thereby the only mannose specific binding protein that is not member of lectin family. This evidence provides further support on the use of Abmb as pharmaceutical or medicinal agent. Its molecular globularity that may contribute to its lack of agglutination capacity was also evaluated.
Collapse
|
5
|
Rachmawati H, Sundari S, Nabila N, Tandrasasmita OM, Amalia R, Siahaan TJ, Tjandrawinata RR, Ismaya WT. Orf239342 from the mushroom Agaricus bisporus is a mannose binding protein. Biochem Biophys Res Commun 2019; 515:99-103. [PMID: 31128918 DOI: 10.1016/j.bbrc.2019.05.107] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2019] [Accepted: 05/16/2019] [Indexed: 12/18/2022]
Abstract
A recently discovered lectin-like protein from mushroom tyrosinase designated as orf239342 inhibits proliferation of the MCF-7 breast cancer cells. This characteristic is likely derived from its ability to recognize sugar entity on the cell surface. Thereby, the binding specificity of orf239342 to sugars was studied. Orf239342 was found to bind specifically to mannose upon analysis with the surface plasmon resonance technique. Finally, our in vitro study showed that mannose impeded orf239342 ability to inhibit proliferation of the MCF-7 breast cancer cells, providing further evidence for the mannose binding onto the protein. Our finding is a breakthrough to characterise orf239342 i.e. to define its functioning in the mushroom, association to the tyrosinase, or even possible application in breast cancer therapy. In addition, the finding allows the more appropriate designation of the protein as Agaricus bisporus mannose binding-protein (AbMb).
Collapse
|
6
|
Diana D, Ismaya WT, Meidianto VF, Tandrasasmita OM, Tjandrawinata RR, Rachmawati H. Bioconjugation of Captopril-Light Subunit of Agaricus bisporus Mushroom Tyrosinase: Characterization and Potential Use as a Drug Carrier for Oral Delivery. Biol Pharm Bull 2018; 41:1837-1842. [PMID: 30259884 DOI: 10.1248/bpb.b18-00553] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
We show that a lectin like protein from the mushroom Agaricus bisporus (LSMT) is capable to permeate the epithelial monolayer barrier of the intestine ex vivo. The protein is not toxic or immunogenic upon prolonged administration and elevated dose in mice. Thus, it could be a candidate as a drug carrier for oral administration. However, its permeability should be tested after the protein has been modified, mimicking the condition in which it is used as a drug carrier. The protein was conjugated to captopril, the selected model of a Biopharmaceutical Classification System (BCS) class III drug, with high solubility but poor permeability. The drug was conjugated to LSMT that had been modified with 4-succinimidyloxycarbonyl-alpha-methyl-2-pyridyldithiotoluene (SMPT) as a linker. The success of LSMT modification was confirmed with TLC and MS; the latter also indicated the amount of captopril molecule linked. The modified LSMT could permeate through the intestinal monolayer barrier, and thus could be absorbed in the intestine after modification. The modified protein appears to remain stable after incubation in simulated gastrointestinal fluids. This pioneering work provides an essential basis for further development of the protein as a drug carrier for oral administration.
Collapse
Affiliation(s)
- Diana Diana
- Research group of Pharmaceutics, School of Pharmacy, Bandung Institute of Technology
| | | | | | | | | | - Heni Rachmawati
- Research group of Pharmaceutics, School of Pharmacy, Bandung Institute of Technology.,Research Center for Nanosciences and Nanotechnology, Bandung Institute of Technology
| |
Collapse
|